Inhaled mometasone furoate reduces oral prednisone usage and improves lung function in severe persistent asthma

Jill P. Karpel, Anjuli Nayak, William Lumry, Timothy J. Craig, Edward Kerwin, James E. Fish, Barry Lutsky

Research output: Contribution to journalArticlepeer-review

29 Scopus citations


Objective: The reduction of oral prednisone use by mometasone furoate (MF) delivered by HFA-227 metered dose inhaler (MDI) was examined in oral corticosteroid (OCS)-dependent patients with severe persistent asthma. Methods: A 3-month, double-blind, placebo-controlled clinical trial (n = 123), followed by a 9-month open-label phase (n = 120). The study was conducted at 26 medical centers in the United States. Patients were randomized to treatment with MF-MDI 400 or 800 μg twice-daily (bid) doses, or placebo in the double-blind trial. All patients received MF in the open-label phase. Results: At the endpoint of the double-blind trial, MF-MDI 400 and 800 μg bid reduced the daily OCS dose by 39.4% and 31.1%, respectively, while placebo increased the OCS dose by 107.2% (P<0.01). The OCS requirement was reduced by 50% or more in 63% and 60% of patients treated with MF-MDI 400 and 800 μg bid, respectively, compared with 14% of patients receiving placebo. After 12 weeks, despite prednisone reductions, pulmonary function, asthma symptoms, albuterol use, nocturnal awakenings, and physician-evaluated response to therapy also showed significant improvement with MF-MDI treatment compared with placebo. Further reductions in OCS requirements were achieved with long-term MF-MDI treatment in the open-label phase, with an overall 67% reduction in prednisone usage and 51% of patients completely eliminating prednisone usage by the 1-year time point. Conclusion: MF delivered by HFA-227 MDI significantly reduces daily OCS use compared with placebo and facilitates elimination of OCS use in patients with severe persistent asthma.

Original languageEnglish (US)
Pages (from-to)628-637
Number of pages10
JournalRespiratory Medicine
Issue number3
StatePublished - Mar 2007

All Science Journal Classification (ASJC) codes

  • Pulmonary and Respiratory Medicine


Dive into the research topics of 'Inhaled mometasone furoate reduces oral prednisone usage and improves lung function in severe persistent asthma'. Together they form a unique fingerprint.

Cite this